Top-Rated StocksTop-RatedNASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis $103.83 -7.29 (-6.56%) Closing price 04:00 PM EasternExtended Trading$104.40 +0.58 (+0.55%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Insmed Stock (NASDAQ:INSM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Insmed alerts:Sign Up Key Stats Today's Range$101.65▼$108.7550-Day Range$98.45▼$134.7552-Week Range$90.39▼$212.75Volume5.39 million shsAverage Volume2.21 million shsMarket Capitalization$22.67 billionP/E RatioN/ADividend YieldN/APrice Target$200.57Consensus RatingBuy Company Overview Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options. Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients. The product is marketed in the United States and has also received regulatory authorization in other major markets, including Europe and Japan. The company is also advancing a pipeline of investigational therapies, including brensocatib, an oral anti-inflammatory treatment being developed for bronchiectasis, and treprostinil palmitil inhalation powder, an inhaled therapy being studied for pulmonary arterial hypertension and other pulmonary conditions. Insmed is headquartered in Bridgewater, New Jersey, and is led by President and Chief Executive Officer Will Lewis.AI Generated. May Contain Errors. Read More Insmed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreINSM MarketRank™: Insmed scored higher than 75% of companies evaluated by MarketBeat, and ranked 219th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 22 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialInsmed has a consensus price target of $200.57, representing about 93.2% upside from its current price of $103.83.Amount of Analyst CoverageInsmed has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insmed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($1.84) to $0.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -25.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -25.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInsmed has a P/B Ratio of 30.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insmed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.05% of the float of Insmed has been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 5.27.Change versus previous monthShort interest in Insmed has recently decreased by 5.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.66 News SentimentInsmed has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Insmed this week, compared to 9 articles on an average week.Search InterestOnly 26 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,320,872.00 in company stock.Percentage Held by Insiders2.10% of the stock of Insmed is held by insiders.Percentage Held by InstitutionsInsmed has minimal institutional ownership at this time.Read more about Insmed's insider trading history. Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INSM Stock News HeadlinesInsmed CFO Sara Bonstein To Step DownOctober 5 at 2:19 PM | rttnews.comInsmed Incorporated Reaffirms Earnings Guidance for the Full-Year 2026October 5 at 2:19 PM | marketscreener.comMThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 5 at 1:00 AM | Reagan Gold Group (Ad)Insmed Chief Financial Officer Sara Bonstein to Step DownOctober 5 at 2:19 PM | finance.yahoo.comInsmed Incorporated Announces Sara Bonstein Steps Down as Chief Financial Officer, Effective October 30, 2026October 5 at 2:19 PM | marketscreener.comMInsmed stock falls as CFO Sara Bonstein to step downOctober 5 at 2:19 PM | uk.finance.yahoo.com3 Healthcare Stocks Showing Why the Sector Still Has Momentum (INSM)Oscar Health, Hinge Health, and Insmed post strong earnings and revenue growth in 2026, with analysts projecting further upside despite sector risks like Medicaid cuts and drug pricing pressure.September 28, 2026 | marketbeat.comDavid Brennan Sells 25,000 Shares of Insmed (NASDAQ:INSM) StockSeptember 12, 2026 | insidertrades.comSee More Headlines INSM Stock Analysis - Frequently Asked Questions How have INSM shares performed this year? Insmed's stock was trading at $174.04 on January 1st, 2026. Since then, INSM stock has decreased by 40.3% and is now trading at $103.83. How were Insmed's earnings last quarter? Insmed, Inc. (NASDAQ:INSM) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.61. Insmed's revenue was up 296.1% on a year-over-year basis. Read the conference call transcript. Who are Insmed's major shareholders? Top institutional shareholders of Insmed include Versant Capital Management Inc and CX Institutional. Insiders that own company stock include Melvin Md Sharoky, William Lewis, John Drayton Wise, Roger Adsett, David W J Mcgirr, Martina MD Flammer, Sara Bonstein, Elizabeth M Anderson, Leo Lee, Orlov S Nicole Schaeffer, David R Brennan, Michael Alexander Smith, Clarissa Desjardins and Clarissa Desjardins. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/06/2026Today10/05/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 INSM's financial health is in the Green zone, according to TradeSmith. INSM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INSM CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees1,664Year FoundedN/APrice Target and Rating Average Price Target for Insmed$200.57 High Price Target$263.00 Low Price Target$167.00 Potential Upside/Downside+93.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)($4.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.28 billion Net Margins-76.94% Pretax Margin-76.40% Return on Equity-123.94% Return on Assets-44.30% Debt Debt-to-Equity Ratio0.74 Current Ratio3.72 Quick Ratio3.40 Sales & Book Value Annual Sales$606.42 million Price / Sales37.39 Cash FlowN/A Price / Cash FlowN/A Book Value$3.46 per share Price / Book30.01Miscellaneous Outstanding Shares218,380,000Free Float213,796,000Market Cap$22.67 billion OptionableOptionable Beta0.83 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:INSM) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
